Volume 14, Number 3—March 2008
Geographic Linkage and Variation in Cryptosporidium hominis
UK Cryptosporidium hominis isolates have previously shown slight PCR fragment length polymorphism at multiple loci. To further investigate transmission, we conducted a case–control study and sequenced the GP60 locus from 115 isolates. Nine subtypes were identified; IbA10G2 predominated. Having a non-IbA10G2 subtype was significantly linked to recent travel outside Europe.
Cryptosporidium hominis, a human-adapted species of the protozoan parasite Cryptosporidium, causes ≈50% of the reported cryptosporidiosis cases in the United Kingdom each year (1). Risk factors for C. hominis have been identified as traveling abroad and changing diapers of children (2). However, studies using multilocus fragment typing of mini- and microsatellite DNA markers have shown that C. hominis isolates from the United Kingdom are genetically very similar (3,4), and no associations between C. hominis subtype and risk have been identified (4). To explore whether a more detailed examination of genomic DNA could benefit public health, we used sequence analysis of the widely studied and highly variable GP60 gene to reexamine C. hominis isolates from a case–control study of sporadic cryptosporidiosis (2).
A total of 115 C. hominis isolates were collected and confirmed during a case–control study of human cryptosporidiosis in Wales and northwest England (2). To identify subtypes, we analyzed the DNA sequences of an ≈850-bp region of the GP60 gene encompassing the polyserine tract (variable numbers and forms of a repeating sequence of 3 nucleotides coding for the amino acid serine) and the hypervariable downstream region (5). We used a nested PCR protocol with primary PCR primers AL3531 and AL3535 and secondary primers AL3532 and AL3534. PCR products were sequenced in both directions.
The microsatellite triplet codons were categorized according to the number of trinucleotide repeats (TCA, TCG, or TCT) coding for the amino acid serine (6), and the nomenclature was expanded for subtype family Ia to include the number of repeats (e.g., R1, R2) of the sequence AA(A/G)ACGGTGGTAAGG after the microsatellite region (7). Sequence data for representative isolates were deposited in GenBank (accession nos. EU161648–EU161655, EF214734, and EF214735). We then investigated subtypes for relationships with reported exposures by using single-variable analysis performed in SPSS 12.0 version (SPSS Inc., Chicago, IL, USA).
Of 115 C. hominis isolates, 14 were not typeable at the GP60 locus (12 did not amplify and 2 gave equivocal reactions); typeability was 87.8%. Nine subtypes were identified but 92 (91.1%) typeable isolates were IbA10G2. Each of the other identified types contained only 1 isolate member except for IgA24, which contained 2. This resulted in a low discriminatory power of 0.171.
More persons with subtypes other than IbA10G2 had a history of recent foreign travel (5/9, 55.6%) than did those with IbA10G2 (27/92, 29.3%), although this was not statistically significant (p = 0.1374 [Fisher exact test], odds ratio [OR] 3.01, 95% confidence interval [CI] 0.59–16.20). However, all 5 case-patients with other subtypes reported travel history outside Europe, 3 to Pakistan (subtypes IaA12R3, IaA22R2, and IaA30R3), 1 to Kenya (IaA25R3), and 1 to New Zealand (IgA24) while only 3 case-patients with IbA10G2 types were known to have traveled outside Europe (to Tunisia and Turkey) (Table 1). All those who reported travel within Europe had subtype IbA10G2.
Four case-patients who had not traveled outside the United Kingdom had non-IbA10G2 alleles, but with the exception of IgA24, these were different from the subtypes found in case- patients who had traveled outside Europe. The relationship between travel outside Europe and GP60 subtypes was statistically significant (p = 0.00008 [Fisher exact test], OR 37.08, 95% CI 4.76–303.65; Table 2). No other epidemiologic associations were present.
Although GP60 sequence typing had very low discriminatory power for UK C. hominis isolates, our findings are in agreement with previous findings based on multiple loci that C. hominis appears to be highly conserved in the United Kingdom (3,4). DNA sequencing of a substantial proportion of the GP60 gene, including the microsatellite region, provides higher resolution data than investigating microsatellite length polymorphisms, which may mask differences in sequence (8); here, DNA sequencing facilitated identification of a significant link between subtype and foreign travel outside Europe. Subtype IbA10G2 is very clearly predominant in the United Kingdom. Subtype family Ib and the IbA10G2 subtype have been reported in Europe both in sporadic cases and outbreaks (9–12) and occur worldwide (12). The conclusion of Cohen et al. (11), that Ib is the predominant C. hominis allele associated with waterborne outbreaks, is explained if this is the most common allele causing human cryptosporidiosis in Europe, as it is in the United Kingdom, and is therefore predominant in human sewage.
In nonindustrialized countries, a greater variety of C. hominis subtypes have been reported (7,8,13,14). Of the 3 isolates found in case-patients returning from Pakistan, IaA12R3 had been isolated from a patient from Nepal (GenBank accession no. AY167595); IaA22R2 and IaA30R3 had not been reported previously. Subtype IaA25R3 was found in a case-patient returning from Kenya and was homologous to a C. hominis reference strain (TU502) of Ugandan origin (GenBank accession no. XM_663000). Notably, of the 4 case-patients with non-IbA10G2 subtypes who did not report foreign travel, 1 had the IgA24 subtype, which matched an isolate from Northern Ireland (GenBank accession no. EF214734), and may well circulate in the United Kingdom; IaA23R4 was homologous to isolates from the United States (GenBank accession no. AF164504) and Canada (GenBank accession no. DQ192510); and IfA12G1 had been identified in Australia (12).
C. hominis is highly conserved in indigenous UK case-patients, and subtypes other than IbA10G2 are linked to recent foreign travel outside Europe. It is not possible to predict whether this apparent stability will remain or whether it will be influenced by international travel.
Dr Chalmers is head of the UK Cryptosporidium Reference Unit, National Public Health Service for Wales. Her main interests are the epidemiology, management, and control of Cryptosporidium and cryptosporidiosis.
We thank Dr Guy Robinson for scientific support.
This project was funded by the Department for Food, Environment and Rural Affairs and managed by the Drinking Water Inspectorate.
- Nichols G, Chalmers R, Lake I, Sopwith W, Regan M, Hunter PR, Cryptosporidiosis: a report on the surveillance and epidemiology of Cryptosporidium infection in England and Wales. Marlow, Bucks (UK): Foundation for Water Research; 2006 [cited 22 Jan 2008]. Available from http://www.fwr.org
- Hunter PR, Hughes LS, Woodhouse S, Syed Q, Verlander N, Chalmers RM, Case-control study of sporadic cryptosporidiosis with genotyping. Emerg Infect Dis. 2004;10:1241–9.
- Mallon ME, MacLeod A, Wastling JM, Smith H, Tait A. Multilocus genotyping of Cryptosporidium parvum type 2: population genetics and sub-structuring. Infect Genet Evol. 2003;3:207–18.
- Hunter PR, Hadfield SJ, Wilkinson D, Lake IR, Harrison FCD, Chalmers RM. Subtypes of Cryptosporidium parvum in humans and disease risk. Emerg Infect Dis. 2007;13:82–8.
- Alves M, Xiao L, Sulaiman I, Lal AA, Matos O, Antunes F. Subgenotype analysis of Cryptosporidium isolates from humans, cattle, and zoo ruminants in Portugal. J Clin Microbiol. 2003;41:2744–7.
- Sulaiman IM, Hira PR, Zhou L, Al-Ali FM, Al-Shelahi FA, Shweiki HM, Unique endemicity of cryptosporidiosis in children in Kuwait. J Clin Microbiol. 2005;43:2805–9.
- Cama VA, Ross JM, Crawford S, Kawai V, Chavez-Valdez R, Vargas D, Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected persons. J Infect Dis. 2007;196:684–91.
- Gatei W, Das P, Dutta P, Sen A, Cama V, Lal AA, Multilocus sequence typing and genetic structure of Cryptosporidium hominis from children in Kolkata, India. Infect Genet Evol. 2007;7:197–205.
- Glaberman S, Moore JE, Lowery CJ, Chalmers RM, Sulaiman I, Elwin K, Three drinking-water-associated cryptosporidiosis outbreaks, Northern Ireland. Emerg Infect Dis. 2002;8:631–3.
- Chalmers RM, Ferguson C, Cacciò SM, Gasser RB, El-Osta YGA, Heijnen L, Direct comparison of selected methods for genetic categorisation of Cryptosporidium parvum and Cryptosporidium hominis species. Int J Parasitol. 2005;35:397–410.
- Cohen S, Dalle F, Gallay A, Di Palma M, Bonnin A, Ward HD. Identification of Cpgp40/15 Type Ib as the predominant allele in isolates of Cryptosporidium spp. from a waterborne outbreak of gastroenteritis in South Burgundy, France. J Clin Microbiol. 2006;44:589–91.
- Obrien E, McInnes L, Ryan U. Cryptosporidium GP60 genotypes from humans and domesticated animals in Australia, North America and Europe. Exp Parasitol. 2008;118:118–21.
- Peng MM, Meshnick SR, Cunliffe NA, Thindwa BD, Hart CA, Broadhead RL, Molecular epidemiology of cryptosporidiosis in children in Malawi. J Eukaryot Microbiol. 2003;50(suppl):557–9.
- Ajjampur SSR, Gladstone BP, Selvappandian D, Muliyil JP, Ward H, Kang G. Molecular and spatial epidemiology of cryptosporidiosis in children in a semiurban community in South India. J Clin Microbiol. 2006;45:915–20.
- Table 1. Travel history and Cryptosporidium hominis GP60 subtypes in sporadic cases, United Kingdom
- Table 2. Travel outside Europe and Cryptosporidium hominis GP60 subtypes in sporadic cases, United Kingdom
Suggested citation for this article: Chalmers RM, Hadfield SJ, Jackson CJ, Elwin K, Xiao L, Hunter P. Geographic linkage and variation in Cryptosporidium hominis. Emerg Infect Dis [serial on the Internet]. 2008 Mar [date cited]. Available from http://wwwnc.cdc.gov/eid/article/14/3/07-1320
Please use the form below to submit correspondence to the authors or contact them at the following address:
Rachel M. Chalmers, UK Cryptosporidium Reference Unit, National Public Health Service, Microbiology Swansea, Singleton Hospital, Swansea, SA2 8QA, Wales, UK;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 07, 2010
- Page last updated: July 07, 2010
- Page last reviewed: July 07, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)